Title:
PHARMACEUTICAL COMPOUND USED AS JAK KINASE INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2022/057770
Kind Code:
A1
Abstract:
Provided is a pharmaceutical compound. The pharmaceutical compound is a compound represented by the following structural formula or a stereoisomer, a geometrical isomer, a tautomer, a racemate, a hydrate, a solvate, a metabolite and a pharmaceutically acceptable salt or prodrug thereof, wherein R represents 1 to 3 substituents on a benzene ring, and each of the 1 to 3 substituents is independently selected from halogen or a cyano group. The pharmaceutical compound of the present invention may inhibit JAK kinase, and more particularly may be used as a JAK1/Tyk2 dual inhibitor and a Tyk2 specific inhibitor. More specifically, the pharmaceutical compound of the present invention may be used for preventing or treating autoimmune diseases, such as rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, systemic lupus erythematosus, type I diabetes, Sjögren's syndrome, vasculitis, alopecia areata, psoriasis, and vitiligo, or other inflammatory skin diseases such as atopic dermatitis, eczema, acne and hidradenitis suppurativa. Formula (0)
More Like This:
Inventors:
XING LI (CN)
FANG WENKUI (CN)
LI GUANQUN (CN)
CAI YUTING (CN)
WANG XIAOLEI (CN)
PAN XIANG (CN)
ZHU WENHAO (CN)
WANG YANG (CN)
WANG ZENGQUAN (CN)
FANG WENKUI (CN)
LI GUANQUN (CN)
CAI YUTING (CN)
WANG XIAOLEI (CN)
PAN XIANG (CN)
ZHU WENHAO (CN)
WANG YANG (CN)
WANG ZENGQUAN (CN)
Application Number:
PCT/CN2021/118025
Publication Date:
March 24, 2022
Filing Date:
September 13, 2021
Export Citation:
Assignee:
TECHNODERMA MEDICINES INC (CN)
International Classes:
C07D403/12; A61K31/506; A61P1/04; A61P3/10; A61P9/10; A61P17/00; A61P17/10; A61P29/00; A61P37/02
Foreign References:
| CN111961037A | 2020-11-20 | |||
| CN110627775A | 2019-12-31 | |||
| CN110862376A | 2020-03-06 | |||
| CN103298794A | 2013-09-11 | |||
| CN108368091A | 2018-08-03 |
Attorney, Agent or Firm:
ZHONG LUN LAW FIRM (CN)
Download PDF: